血清sNRP-1、NINJ1与脓毒症患者病情程度的关系及对预后的预测效能OA
Relationship between serum sNRP-1 and NINJ1 levels with disease severity of patients with sepsis and their predictive efficacy for prognosis
目的 探讨血清可溶性神经纤毛蛋白-1(sNRP-1)、神经诱导损伤蛋白1(NINJ1)水平与脓毒症患者病情程度的关系及对预后的预测效能.方法 回顾性选取2021年1月至2024年5月常熟市第一人民医院重症医学科收治的脓毒症患者265例(脓毒症组)和同期本院健康体检志愿者135人(对照组),脓毒症患者根据病情程度分为普通脓毒症组128例和脓毒性休克组137例,根据90 d预后分为死亡组81例和存活组184例.收集患者临床资料,采用酶联免疫吸附试验检测血清sNRP-1、NINJ1水平.采用Spearman秩相关分析脓毒症患者血清sNRP-1、NINJ1水平与序贯器官衰竭评估(SOFA)评分和急性生理学和慢性健康状况评价Ⅱ(APACHE Ⅱ)评分的相关性;采用多因素logistic回归分析影响脓毒症患者死亡的因素;采用ROC曲线评估血清sNRP-1、NINJ1水平预测脓毒症患者死亡的效能.结果 与对照组比较,脓毒症组患者血清sNRP-1、NINJ1水平均升高(均P<0.01).与普通脓毒症组比较,脓毒性休克组患者血清sNRP-1、NINJ1水平均升高(均P<0.01).Spearman秩相关分析显示,脓毒症患者血清sNRP-1、NINJ1水平与 SOFA评分(rs=0.735、0.757,均P<0.001)、APACHE Ⅱ 评分(rs=0.716、0.752,均P<0.001)均呈正相关.265例脓毒症患者90 d 死亡率为30.57%(81/265).与存活组比较,死亡组患者血清sNRP-1、NINJ1水平均升高(均P<0.05).多因素logistic回归分析显示,sNRP-1水平高、NINJ1水平高均是影响脓毒症患者死亡的独立危险因素(均P<0.05).ROC曲线分析显示,血清sNRP-1、NINJ1水平单独和联合预测脓毒症患者死亡的AUC为0.791、0.813、0.890,两者联合预测的效能高于单独预测(均P<0.05).结论 脓毒症患者血清sNRP-1、NINJ1水平升高,与病情加重及死亡风险增加有关,可能成为脓毒症患者病情及预后评估的标志物.
Objective To investigate the relationship of serum soluble neuropilin-1(sNRP-1)and nerve injury-induced protein 1(NINJ1)levels with disease severity of patients with sepsis and their predictive efficacy for prognosis.Methods A total of 265 sepsis patients(sepsis group)admitted to the Department of Critical Care Medicine of Changshu First People's Hospital from January 2021 to May 2024,and 135 healthy volunteers(control group)who received health examination at the same hospital during the same period were enrolled.Sepsis patients were further divided into a general sepsis group(n=128)and a septic shock group(n=137)based on disease severity,and they were divided into a death group(n=81)and a survival group(n=184)according to 90-day prognosis.Clinical data of patients were collected,and serum sNRP-1 and NINJ1 levels were measured by enzyme-linked immunosorbent assay.Spearman rank correlation was used to analyze the correlation of serum sNRP-1 and NINJ1 levels with Sequential Organ Failure Assessment(SOFA)score and Acute Physiology and Chronic Health Evaluation Ⅱ(APACHE Ⅱ)score in sepsis patients.Multivariate logistic regression analysis was performed to identify factors influencing mortality of sepsis patients.Receiver operating characteristic(ROC)curve analysis was used to evaluate the efficacy of serum sNRP-1 and NINJ1 levels in predicting mortality of sepsis patients.Results Compared with the control group,serum sNRP-1 and NINJ1 levels were significantly higher in the sepsis group(both P<0.01).Compared with the general sepsis group,serum sNRP-1 and NINJ1 levels were also significantly higher in the septic shock group(both P<0.01).Spearman rank correlation analysis showed that serum sNRP-1 and NINJ1 levels were positively correlated with SOFA score(rs=0.735,0.757,respectively,both P<0.001)and APACHE Ⅱ score(rs=0.716,0.752,respectively,both P<0.001).The 90-day mortality rate of the 265 sepsis patients was 30.57%(81/265).Compared with the survival group,serum sNRP-1 and NINJ1 levels were significantly higher in the death group(both P<0.05).Multivariate logistic regression analysis showed that high levels of sNRP-1 and NINJ1 were independent risk factors for mortality in sepsis patients(both P<0.05).ROC curve analysis showed that the area under the curve(AUC)for serum sNRP-1 and NINJ1 alone,and their combination in predicting mortality of sepsis patients were 0.791,0.813,and 0.890,respectively,with the combined prediction efficacy being significantly higher than that of either marker alone(both P<0.05).Conclusion Elevated serum levels of sNRP-1 and NINJ1 in sepsis patients are associated with disease severity and increased risk of mortality,suggesting their potential as biomarkers for disease assessment and prognosis prediction in sepsis patients.
汪易岚;张茜;顾燕;周维一
215500 常熟市第一人民医院重症医学科215500 常熟市第一人民医院重症医学科215500 常熟市第一人民医院重症医学科215500 常熟市第一人民医院重症医学科
脓毒症可溶性神经纤毛蛋白-1神经诱导损伤蛋白1病情预后
SepsisSoluble neuropilin-1Nerve injury-induced protin 1Disease severityPrognosis
《浙江医学》 2026 (2)
151-156,6
苏州市临床重点病种诊疗技术专项项目(LCZX201922)
评论